Romero Sally A D, Li Qing Susan, Orlow Irene, Gonen Mithat, Su Hui-Chun Irene, Mao Jun J
Memorial Sloan Kettering Cancer Center, New York, NY.
Moores Cancer Center, University of California San Diego, La Jolla, CA.
Menopause. 2020 Aug;27(8):913-917. doi: 10.1097/GME.0000000000001545.
Because hot flashes are a common symptom experienced by women with breast cancer, we sought to explore genetic predictors associated with response to acupuncture for the treatment of hot flashes.
Using data from our completed randomized controlled trial (Clinicaltrials.gov identifier: NCT01005108) on hot flashes among breast cancer survivors who provided biomarker collection (N = 108), we extracted and assayed DNA for single nucleotide polymorphisms in genes involved in neurotransmission, thermoregulation, and inflammation (ADORA1, COMT, TCL1A, and TRPV1). For our primary outcome we classified individuals with a 50% or more reduction in their hot flash composite score at the end of treatment as responders. We used Fisher exact test to identify individual and combined single nucleotide polymorphisms associated with treatment response.
Among women (N = 57) who received acupuncture treatment (electro or sham), we found that women who were carriers of at least one of these six genotypes (ADORA1 rs41264025-GA or rs16851029-GG or rs12744240-GT, COMT rs6269-GA, TCL1A rs2369049-GG, and TRPV1 rs8065080-TT) were more likely to respond to acupuncture for hot flashes than noncarriers (70.3% vs 37.5%, P = 0.035). These six genotypes were not associated with response in women (N = 51) who received pharmacological hot flash treatment (gabapentin or placebo pill; 37.5% vs 37.5%, P = 1.0).
In this exploratory, proof of concept study, we identified six genotypes that may predict response to acupuncture for hot flashes in breast cancer survivors. If confirmed by future studies, these findings may inform the development of personalized acupuncture for managing hot flashes.
由于潮热是乳腺癌女性常见的症状,我们试图探索与针刺治疗潮热反应相关的基因预测指标。
利用我们已完成的关于乳腺癌幸存者潮热的随机对照试验(Clinicaltrials.gov标识符:NCT01005108)的数据,这些幸存者提供了生物标志物样本(N = 108),我们提取并检测了参与神经传递、体温调节和炎症的基因(ADORA1、COMT、TCL1A和TRPV1)中的单核苷酸多态性。对于我们的主要结局,我们将治疗结束时潮热综合评分降低50%或更多的个体分类为有反应者。我们使用Fisher精确检验来识别与治疗反应相关的个体和组合单核苷酸多态性。
在接受针刺治疗(电针或假针)的女性(N = 57)中,我们发现携带这六种基因型(ADORA1 rs41264025 - GA或rs16851029 - GG或rs12744240 - GT、COMT rs6269 - GA、TCL1A rs2369049 - GG和TRPV1 rs8065080 - TT)中至少一种的女性比非携带者更有可能对针刺治疗潮热有反应(70.3%对37.5%,P = 0.035)。这六种基因型与接受药物潮热治疗(加巴喷丁或安慰剂丸)的女性(N = 51)的反应无关(37.5%对37.5%,P = 1.0)。
在这项探索性的概念验证研究中,我们确定了六种基因型,它们可能预测乳腺癌幸存者对针刺治疗潮热的反应。如果未来的研究证实,这些发现可能为开发个性化的针刺治疗潮热提供依据。